(Q34173071)

31 July 2017

1 reference

title

A review of the history, properties, and use of the immunomodulatory compound lenalidomide. (English)

1 reference

31 July 2017

Robert Douglas Knight

2

object named as

Robert Knight

1 reference

31 July 2017

Jerome B Zeldis

1

1 reference

31 July 2017

Mohamad Hussein

3

1 reference

31 July 2017

Rajesh Chopra

4

1 reference

31 July 2017

George Muller

5

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Annals of the New York Academy of Sciences

31 July 2017

1 reference

31 July 2017

1222

1 reference

31 July 2017

76-82

1 reference

Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

31 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Mechanism of action of lenalidomide in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Phase I study of oral lenalidomide in patients with refractory metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Management of patients with chronic lymphocytic leukemia treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05974.X

10.1111/J.1749-6632.2011.05974.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference